Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study
Shah, Parth, Glueck, Charles J., Goldenberg, Naila, Min, Sarah, Mahida, Chris, Schlam, Ilana, Rothschild, Matan, Huda, Ali, Wang, PingVolume:
16
Language:
english
Journal:
Lipids in Health and Disease
DOI:
10.1186/s12944-017-0416-7
Date:
December, 2017
File:
PDF, 687 KB
english, 2017